Citi Pharma Limited

CPHL

PK0126201018

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
31.16 ^PKR	-1.24%		+6.02%	+31.26%

2023	Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI
2023	33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2023.	CI

Citi Pharma Ltd. Announces Board Changes

August 06, 2021 at 01:43 pm EDT

Citi Pharma Ltd. announced that Mr. Farzin Khan has been appointed as director of the company with effect from August 2, 2021 in place of Mr. Rana Shakeel Shaukat.

Latest news about Citi Pharma Limited

Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-06	CI
33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2023.	23-06-23	CI
Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-04-27	CI
Citi Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-28	CI
Citi Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-18	CI
Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-10-11	CI
Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-07-23	CI
33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2022.	22-06-23	CI
Citi Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-06-03	CI
Citi Pharma Limited Announces Earnings Results for the Year Ended June 30, 2021	21-09-30	CI
Citi Pharma Limited Announces Final Cash Dividend for the Year Ended June 30, 2021	21-09-30	CI
Citi Pharma Ltd. Announces Board Changes	21-08-06	CI
Citi Pharma Limited has completed an IPO in the amount of PKR 2.326144 billion.	21-07-08	CI
Citi Pharma Limited has filed an IPO in the amount of PKR 2.849526 billion.	21-02-12	CI

Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.16

Average target price

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CITI PHARMA LIMITED	+31.26%	25.92M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.60%	364B
MERCK & CO., INC.	+20.83%	326B
ABBVIE INC.	+5.69%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.77%	167B
PFIZER, INC.	+0.10%	161B

Other Pharmaceuticals

Citi Pharma Limited

Equities

CPHL

PK0126201018

Pharmaceuticals

Citi Pharma Ltd. Announces Board Changes

Latest news about Citi Pharma Limited

Chart Citi Pharma Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

Annual profits - Rate of surprise

Sector Other Pharmaceuticals